{
    "Trade/Device Name(s)": [
        "IDS-iSYS Ostase\u00ae BAP"
    ],
    "Submitter Information": "Immunodiagnostic Systems Limited",
    "510(k) Number": "K200475",
    "Predicate Device Reference 510(k) Number(s)": [
        "K972666"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIN"
    ],
    "Summary Letter Date": "August 27, 2020",
    "Summary Letter Received Date": "August 31, 2020",
    "Submission Date": "September 28, 2020",
    "Regulation Number(s)": [
        "21CFR862.1050"
    ],
    "Regulation Name(s)": [
        "Alkaline phosphatase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Bone-specific alkaline phosphatase (BAP)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "IDS System"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoenzymetric assay",
        "Automated immunoassay"
    ],
    "Methodologies": [
        "Quantitative measurement",
        "Automated immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for IDS-iSYS Ostase\u00ae BAP automated immunoenzymetric assay for bone-specific alkaline phosphatase on the IDS System",
    "Indications for Use Summary": "Quantitative determination of bone-specific alkaline phosphatase in human serum to aid in management of postmenopausal osteoporosis and Paget\u2019s disease, used with other clinical and laboratory data",
    "fda_folder": "Clinical Chemistry"
}